Mesoblast Ltd Sp ADR (MBLTY) 12.5200 $MBLTY
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.81 (unch), NBS: 2.98 (+0.06), OSIR: 17.56 (+0.84), BCLI: 4.63 (+0.31), MDVN: 132.44 (+0.38), INO: 9.78 (-0.18), CYTX: 1.24 (-0.02), STEM: 1.00 (-0.01), JUNO: 60.39 (+1.15), ATHX: 3.03 (+0.03), CUR: 1.94 (+0.07), BLUE: 126.34 (+1.49), VRTX: 128.47 (+2.83), AMGN: 163.38 (+1.89), KERX: 12.42 (+0.09), OMER: 24.58 (+0.44), KITE: 58.34 (+0.22), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), TEVA: 66.37 (-0.77)
Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency
GlobeNewswire - Tue Apr 07, 7:25PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that following positive feedback from its recent meeting with the European Medicines Agency (EMA), it intends to expand the Phase 3 clinical program of its product candidate MPC-06-ID in the treatment of chronic low back pain due to degenerative disc disease to include sites in the European Union (EU).
Mesoblast Key Patent Allowed in Japan for the Treatment of Heart Diseases, Stroke, and Other Vascular Conditions
GlobeNewswire - Thu Mar 26, 10:33PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Japanese Patent Office has allowed a key patent covering the use of the Company's proprietary adult Mesenchymal Precursor Cells (MPCs) for the formation and repair of blood vessels in ischemic tissues. Japanese patent 2006-503990, entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation', covers the use of these cells derived from bone marrow, adipose tissue and dental pulp.
Mesoblast Selected for Fast Track Access to Potential Investment Incentives in Japan
GlobeNewswire - Wed Mar 18, 6:32PM CDT
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been selected by the Japan External Trade Organization (JETRO) as the only regenerative medicine company worldwide to receive fast track access to potential investment incentives across all levels of government in Japan. Mesoblast will receive a specially tailored market and government incentive roadmap aimed at providing a more attractive business environment.
MSB: 15.80 (+1.08)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 35.44 (+0.41), OPHT: 49.99 (+2.36), GSK: 48.23 (+0.51), PFNX: 18.98 (+2.17), LPTN: 2.49 (+0.18), AGN: 240.22 (+2.88), AAVL: 40.69 (+1.27), OHRP: 2.80 (+0.11), NVS: 103.58 (+1.01)
IMPROVED SURVIVAL IN CHILDREN WITH GRAFT VERSUS HOST DISEASE WHO RESPOND TO MESOBLAST'S CELL THERAPY
GlobeNewswire - Sun Feb 15, 5:33PM CST
Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for severe steroid-resistant acute Graft Versus Host Disease (aGVHD) were presented at the 2015 American Society for Blood and Marrow Transplantation meeting in San Diego on 14 February.
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
CAPR: 8.00 (unch), OCAT: 6.63 (-0.03), VCEL: 3.72 (+0.01), PSTI: 2.81 (unch), NBS: 2.98 (+0.06), GSK: 48.23 (+0.51), IMUC: 0.44 (unch), KITE: 58.34 (+0.22), BAX: 70.57 (+0.42), ONCE: 71.82 (+1.30), JUNO: 60.39 (+1.15), ATHX: 3.03 (+0.03), CUR: 1.94 (+0.07)
Mesoblast Reports 2015 Half-Year Results
GlobeNewswire - Wed Feb 11, 4:49PM CST
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today provided its 2015 half-year financial results and operational highlights. Mesoblast held cash reserves of $149.2 million at 31 December 2014.
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.96 (+0.01), OCAT: 6.63 (-0.03), PSTI: 2.81 (unch)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 425.65 (-0.98), PSTI: 2.81 (unch), ASPX: 100.58 (+0.10), LPTN: 2.49 (+0.18), IBIO: 0.90 (-0.15), FGEN: 29.90 (+0.06), AQXP: 8.47 (+0.22), GALT: 3.26 (+0.02), LLY: 73.92 (+1.56), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), GILD: 101.77 (+0.61), CGEN: 7.27 (+0.11), FPRX: 20.98 (+0.96), CELGZ: 2.89 (+0.04)
Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference
GlobeNewswire - Wed Jan 14, 5:13PM CST
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today presented positive 24-month results from its Phase 2 program for chronic low back pain at the JP Morgan 33rd Annual Healthcare Conference being held in San Francisco.
Stem Cell Therapy Market by Treatment Mode & Therapeutic Applications will reach $330 Million by 2020 - Prominent Players in this Market - Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.) & StemCells, Inc. (U.S.)
M2 - Mon Dec 15, 4:55AM CST
The report "Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020" analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).
Degenerative Disc Disease - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/7637kg/degenerative_disc) has announced the addition of the "Degenerative Disc Disease - Pipeline Review, H2 2013" report to their offering. 'Degenerative Disc Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Degenerative Disc Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease. Degenerative Disc Disease - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources Scope - A snapshot of the global therapeutic scenario for Degenerative Disc Disease. - A review of the Degenerative Disc Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Degenerative Disc Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned: - DePuy Spine - ISTO Technologies - Mesoblast Limited - Yuhan Corporation - Kolon Life Science - AnGes MG - TissueGene - RNL BIO - Discgenics - BioRestorative Therapies For more information visit http://www.researchandmarkets.com/research/76...ative_disc
Spinal Stenosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/d58sg3/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Spinal Stenosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Spinal Stenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - LTT Bio-Pharma Co., Ltd. - Mesoblast Limited - Sucampo Pharmaceuticals, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/d5...l_stenosis
SCMP: 19.92 (+0.14)
Global Regenerative Medicines Market 2014-2020 - Technology, Application and Geography Analysis of the $67 Billion Industry
M2 - Wed Nov 26, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/bx37gm/global) has announced the addition of the "Global Regenerative Medicines Market 2014-2020 - Technology, Application and Geography Analysis of the $67 Billion Industry" report to their offering. The global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process. These medicines are capable of restoring the functionality of cells and tissues. These medicines find applicability in wide range of degenerative disorders including dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications. Researchers are engaged in developing technologies based on biologics, genes, somatic as well as stem cells. The factors driving growth of this market include advancements in stem cell therapy, significance of nanotechnology and increasing incidences of degenerative diseases. Stem cells have unique ability of proliferation and differentiation. These cells can differentiate into any cell lineage. This distinctive characteristic of stem cells has made them of significant importance in this field. Additionally, the utilization of nano-materials in wound care, drug delivery and immunomodulation is opening growth avenues for the regenerative medicine market. However, the stringent regulations and the high cost of treatment act as hindrance for the progress of this market. The increasing focus on stem cells, their applications and the emerging economies would all contribute to the growth of this market. The developing nations are adopting technological advancements at a rapid pace, which would aid in the expansion of this market throughout the globe. KEY BENEFITS - The report provides an evaluation of drivers and restraints in this market, which would affect its growth. An assessment of opportunities is given to understand the growth avenues - The technology segment helps in understanding the present technologies used in this market - The application segment describes the availability of product based on type of diseases and discusses the ongoing studies for other disorders - The segmentation based on geography helps in analyzing advancements in regenerative medicine market throughout the globe - The projections in the report are made by analyzing the current market trends and future market potential for the period of 2013-2020 - The key strategies adopted by the market players are discussed to provide an insight on the winning approaches followed by the companies - Porter's five forces analysis is used to assess the present industrial scenario to help stakeholders in making decisive moves Scope of the Report MARKET BY TECHNOLOGY - Small molecules and Biologics - Gene therapy - Cell therapy MARKET BY APPLICATION - Dermatology - Cardiovascular - CNS - Orthopedic - Dental - Others - Autoimmune disorders - Muscle regeneration - Ocular diseases Companies Mentioned - Advanced Cell Technology - Athersys Inc. - Cytomedix - Cytori Therapeutics - Genzyme - Kinetic Concepts - Mesoblast Ltd. - NuVasive - Shire pharmaceuticals - Stem Cells For more information visit http://www.researchandmarkets.com/research/bx37gm/global
CYTX: 1.24 (-0.02), ATHX: 3.03 (+0.03)
Japanese Legislation Takes Effect for Expedited Approvals of Regenerative Medical Products
GlobeNewswire - Mon Nov 24, 7:07PM CST
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) provided an update to the market on the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act) which takes effect today in Japan. This Act establishes a framework for expedited approval in Japan for regenerative medical products.
MSB: 15.80 (+1.08)
Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting
GlobeNewswire - Wed Nov 12, 5:36PM CST
Mesoblast's Phase 2 trial results in degenerative disc disease were presented today at the North American Spine Society (NASS) Annual Meeting, the premier global conference for spine disease professionals. The key outcome of the trial was that a single injection of Mesoblast's proprietary allogeneic Mesenchymal Precursor Cell (MPC) product resulted in sustained improvements in pain and function at 12 months.
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 425.65 (-0.98), PCYC: 258.35 (+0.57), PSTI: 2.81 (unch), NBS: 2.98 (+0.06), ALDR: 27.92 (+0.64), IDRA: 3.79 (+0.08), SGEN: 37.09 (+0.88), JAZZ: 183.96 (+3.13), ALXN: 182.68 (+5.31), KMDA: 4.53 (+0.02), ATHX: 3.03 (+0.03), NVS: 103.58 (+1.01)
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
GlobeNewswire - Tue Sep 30, 7:18PM CDT
Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR Pharmaceuticals Co Ltd (JCR), has filed with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to receive approval for manufacturing, marketing, and product registration of the allogeneic or "off-the-shelf" Mesenchymal Stem Cell (MSC) product JR-031 for the treatment of acute graft versus host disease (GVHD) in children and adults.
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
PSTI: 2.81 (unch), CGEN: 7.27 (+0.11), SPPI: 6.00 (+0.08), CBLI: 3.67 (-0.02)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.81 (unch), NBS: 2.98 (+0.06), OSIR: 17.56 (+0.84), BCLI: 4.63 (+0.31), MDVN: 132.44 (+0.38), INO: 9.78 (-0.18), CYTX: 1.24 (-0.02), STEM: 1.00 (-0.01), JUNO: 60.39 (+1.15), ATHX: 3.03 (+0.03), CUR: 1.94 (+0.07), BLUE: 126.34 (+1.49), VRTX: 128.47 (+2.83), AMGN: 163.38 (+1.89), KERX: 12.42 (+0.09), OMER: 24.58 (+0.44), KITE: 58.34 (+0.22), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), TEVA: 66.37 (-0.77)
Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency
GlobeNewswire - Tue Apr 07, 7:25PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that following positive feedback from its recent meeting with the European Medicines Agency (EMA), it intends to expand the Phase 3 clinical program of its product candidate MPC-06-ID in the treatment of chronic low back pain due to degenerative disc disease to include sites in the European Union (EU).
Mesoblast Key Patent Allowed in Japan for the Treatment of Heart Diseases, Stroke, and Other Vascular Conditions
GlobeNewswire - Thu Mar 26, 10:33PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Japanese Patent Office has allowed a key patent covering the use of the Company's proprietary adult Mesenchymal Precursor Cells (MPCs) for the formation and repair of blood vessels in ischemic tissues. Japanese patent 2006-503990, entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation', covers the use of these cells derived from bone marrow, adipose tissue and dental pulp.
Mesoblast Selected for Fast Track Access to Potential Investment Incentives in Japan
GlobeNewswire - Wed Mar 18, 6:32PM CDT
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been selected by the Japan External Trade Organization (JETRO) as the only regenerative medicine company worldwide to receive fast track access to potential investment incentives across all levels of government in Japan. Mesoblast will receive a specially tailored market and government incentive roadmap aimed at providing a more attractive business environment.
MSB: 15.80 (+1.08)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 35.44 (+0.41), OPHT: 49.99 (+2.36), GSK: 48.23 (+0.51), PFNX: 18.98 (+2.17), LPTN: 2.49 (+0.18), AGN: 240.22 (+2.88), AAVL: 40.69 (+1.27), OHRP: 2.80 (+0.11), NVS: 103.58 (+1.01)
IMPROVED SURVIVAL IN CHILDREN WITH GRAFT VERSUS HOST DISEASE WHO RESPOND TO MESOBLAST'S CELL THERAPY
GlobeNewswire - Sun Feb 15, 5:33PM CST
Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for severe steroid-resistant acute Graft Versus Host Disease (aGVHD) were presented at the 2015 American Society for Blood and Marrow Transplantation meeting in San Diego on 14 February.
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
CAPR: 8.00 (unch), OCAT: 6.63 (-0.03), VCEL: 3.72 (+0.01), PSTI: 2.81 (unch), NBS: 2.98 (+0.06), GSK: 48.23 (+0.51), IMUC: 0.44 (unch), KITE: 58.34 (+0.22), BAX: 70.57 (+0.42), ONCE: 71.82 (+1.30), JUNO: 60.39 (+1.15), ATHX: 3.03 (+0.03), CUR: 1.94 (+0.07)
Mesoblast Reports 2015 Half-Year Results
GlobeNewswire - Wed Feb 11, 4:49PM CST
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today provided its 2015 half-year financial results and operational highlights. Mesoblast held cash reserves of $149.2 million at 31 December 2014.
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.96 (+0.01), OCAT: 6.63 (-0.03), PSTI: 2.81 (unch)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 425.65 (-0.98), PSTI: 2.81 (unch), ASPX: 100.58 (+0.10), LPTN: 2.49 (+0.18), IBIO: 0.90 (-0.15), FGEN: 29.90 (+0.06), AQXP: 8.47 (+0.22), GALT: 3.26 (+0.02), LLY: 73.92 (+1.56), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), GILD: 101.77 (+0.61), CGEN: 7.27 (+0.11), FPRX: 20.98 (+0.96), CELGZ: 2.89 (+0.04)
Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference
GlobeNewswire - Wed Jan 14, 5:13PM CST
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today presented positive 24-month results from its Phase 2 program for chronic low back pain at the JP Morgan 33rd Annual Healthcare Conference being held in San Francisco.
Stem Cell Therapy Market by Treatment Mode & Therapeutic Applications will reach $330 Million by 2020 - Prominent Players in this Market - Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.) & StemCells, Inc. (U.S.)
M2 - Mon Dec 15, 4:55AM CST
The report "Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020" analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).
Degenerative Disc Disease - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/7637kg/degenerative_disc) has announced the addition of the "Degenerative Disc Disease - Pipeline Review, H2 2013" report to their offering. 'Degenerative Disc Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Degenerative Disc Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease. Degenerative Disc Disease - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources Scope - A snapshot of the global therapeutic scenario for Degenerative Disc Disease. - A review of the Degenerative Disc Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Degenerative Disc Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned: - DePuy Spine - ISTO Technologies - Mesoblast Limited - Yuhan Corporation - Kolon Life Science - AnGes MG - TissueGene - RNL BIO - Discgenics - BioRestorative Therapies For more information visit http://www.researchandmarkets.com/research/76...ative_disc
Spinal Stenosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/d58sg3/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Spinal Stenosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Spinal Stenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - LTT Bio-Pharma Co., Ltd. - Mesoblast Limited - Sucampo Pharmaceuticals, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/d5...l_stenosis
SCMP: 19.92 (+0.14)
Global Regenerative Medicines Market 2014-2020 - Technology, Application and Geography Analysis of the $67 Billion Industry
M2 - Wed Nov 26, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/bx37gm/global) has announced the addition of the "Global Regenerative Medicines Market 2014-2020 - Technology, Application and Geography Analysis of the $67 Billion Industry" report to their offering. The global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process. These medicines are capable of restoring the functionality of cells and tissues. These medicines find applicability in wide range of degenerative disorders including dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications. Researchers are engaged in developing technologies based on biologics, genes, somatic as well as stem cells. The factors driving growth of this market include advancements in stem cell therapy, significance of nanotechnology and increasing incidences of degenerative diseases. Stem cells have unique ability of proliferation and differentiation. These cells can differentiate into any cell lineage. This distinctive characteristic of stem cells has made them of significant importance in this field. Additionally, the utilization of nano-materials in wound care, drug delivery and immunomodulation is opening growth avenues for the regenerative medicine market. However, the stringent regulations and the high cost of treatment act as hindrance for the progress of this market. The increasing focus on stem cells, their applications and the emerging economies would all contribute to the growth of this market. The developing nations are adopting technological advancements at a rapid pace, which would aid in the expansion of this market throughout the globe. KEY BENEFITS - The report provides an evaluation of drivers and restraints in this market, which would affect its growth. An assessment of opportunities is given to understand the growth avenues - The technology segment helps in understanding the present technologies used in this market - The application segment describes the availability of product based on type of diseases and discusses the ongoing studies for other disorders - The segmentation based on geography helps in analyzing advancements in regenerative medicine market throughout the globe - The projections in the report are made by analyzing the current market trends and future market potential for the period of 2013-2020 - The key strategies adopted by the market players are discussed to provide an insight on the winning approaches followed by the companies - Porter's five forces analysis is used to assess the present industrial scenario to help stakeholders in making decisive moves Scope of the Report MARKET BY TECHNOLOGY - Small molecules and Biologics - Gene therapy - Cell therapy MARKET BY APPLICATION - Dermatology - Cardiovascular - CNS - Orthopedic - Dental - Others - Autoimmune disorders - Muscle regeneration - Ocular diseases Companies Mentioned - Advanced Cell Technology - Athersys Inc. - Cytomedix - Cytori Therapeutics - Genzyme - Kinetic Concepts - Mesoblast Ltd. - NuVasive - Shire pharmaceuticals - Stem Cells For more information visit http://www.researchandmarkets.com/research/bx37gm/global
CYTX: 1.24 (-0.02), ATHX: 3.03 (+0.03)
Japanese Legislation Takes Effect for Expedited Approvals of Regenerative Medical Products
GlobeNewswire - Mon Nov 24, 7:07PM CST
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) provided an update to the market on the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act) which takes effect today in Japan. This Act establishes a framework for expedited approval in Japan for regenerative medical products.
MSB: 15.80 (+1.08)
Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting
GlobeNewswire - Wed Nov 12, 5:36PM CST
Mesoblast's Phase 2 trial results in degenerative disc disease were presented today at the North American Spine Society (NASS) Annual Meeting, the premier global conference for spine disease professionals. The key outcome of the trial was that a single injection of Mesoblast's proprietary allogeneic Mesenchymal Precursor Cell (MPC) product resulted in sustained improvements in pain and function at 12 months.
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 425.65 (-0.98), PCYC: 258.35 (+0.57), PSTI: 2.81 (unch), NBS: 2.98 (+0.06), ALDR: 27.92 (+0.64), IDRA: 3.79 (+0.08), SGEN: 37.09 (+0.88), JAZZ: 183.96 (+3.13), ALXN: 182.68 (+5.31), KMDA: 4.53 (+0.02), ATHX: 3.03 (+0.03), NVS: 103.58 (+1.01)
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
GlobeNewswire - Tue Sep 30, 7:18PM CDT
Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR Pharmaceuticals Co Ltd (JCR), has filed with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to receive approval for manufacturing, marketing, and product registration of the allogeneic or "off-the-shelf" Mesenchymal Stem Cell (MSC) product JR-031 for the treatment of acute graft versus host disease (GVHD) in children and adults.
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
PSTI: 2.81 (unch), CGEN: 7.27 (+0.11), SPPI: 6.00 (+0.08), CBLI: 3.67 (-0.02)
